Properties
What is it?
CORVALOL Dosage form: Solution Description: The preparation is a colorless transparent liquid with a specific characteristic aromatic odor. Composition: 20 g ethyl ester of alpha-bromoisovaleric acid, 18.26 g phenobarbital, 1.42 g peppermint oil, 580 ml ethyl alcohol, 0.2 g stabilizer, up to 1 L purified water. Pharmacological group: Complex medicinal product with antispasmodic and sedative action. Pharmacological properties: The antispasmodic and sedative effect of the preparation is due to its components. Ethyl ester of alpha-bromoisovaleric acid has a reflex sedative effect by directly irritating the receptors of the oral cavity and nasopharynx. Phenobarbital suppresses the activating influence of the reticular formation of the midbrain and medulla oblongata on the cerebral cortex, which leads to a decrease in irritating impulses in the cerebral cortex and subcortical structures. A decrease in activating influence, depending on the dose, leads to a sedative, tranquilizing, or hypnotic effect. Corvalol reduces the irritating effect on the centers of blood circulation, coronary and peripheral blood vessels, lowers blood pressure, relieves vascular spasms, especially cardiac spasms. Peppermint oil contains a large amount of essential oils, including approximately 50% menthol and 4-9% menthol esters. These components irritate the "cold" receptors of the oral cavity and reflexively dilate the blood vessels of the heart and brain, relieve smooth muscle spasms, and cause a sedative and weakly choleretic effect. Pharmacokinetics: After oral administration, absorption begins in the sublingual area, and its bioavailability is high (approximately 60-80%). The effect of Corvalol appears quickly (after 5-10 minutes) after holding it in the oral cavity (sublingual absorption) or taking it on a piece of sugar. The effect begins after 15-45 minutes and lasts for 3-6 hours. In patients who have previously used barbituric acid-containing preparations, the duration of Corvalol's action is reduced due to the rapid metabolism of phenobarbital in the liver, where barbiturates induce enzymes. In elderly patients and patients with liver cirrhosis, Corvalol metabolism is reduced, which prolongs the half-life (T½) in these patient groups, necessitating a dose reduction and an increase in the interval between doses. See blog: Corvalol - A medicinal product with antispasmodic and sedative action. Indications: Corvalol is prescribed for increased irritability, insomnia, early stages of hypertension, mild coronary artery spasm, and tachycardia during neuroses. It is also used as a sedative, vasodilator, and antispasmodic agent for intestinal spasms. Dosage and administration: Corvalol is taken orally, independently of food, 3 times a day, 15-30 drops, dissolved in water or on a piece of sugar. If necessary (pronounced tachycardia and coronary artery spasm), the single dose can be increased to 40-50 drops. Side effects: Corvalol is generally well tolerated, even with prolonged use. In isolated cases, drowsiness and dizziness may occur during the day, which disappear upon dose reduction. Overdose: Prolonged use and overdose of the preparation may lead to central nervous system depression, which is leveled by the use of CNS stimulants (caffeine, cordiamine, etc.). In other cases, treatment is symptomatic. Special instructions: The preparation contains 62% alcohol, which can cause impaired coordination and psychomotor reaction speed. Therefore, caution is required when driving vehicles and performing tasks that require maximum concentration when using the preparation. Alcohol consumption should also be avoided when using Corvalol. Contraindications: Hypersensitivity to the components of the preparation, severe heart failure, severe renal and hepatic impairment, pregnancy and lactation. Interactions with other medicinal products: Central nervous system depressants enhance the effect of Corvalol. The preparation weakens the effect of drugs that undergo metabolism in the liver. Shelf life: Indicated on the packaging, and the preparation is not allowed to be used after the indicated date. Dosage form: Solution, contained in 15 ml and 25 ml bottles. Storage conditions: Store in a place protected from light and children at a temperature not exceeding +15°C.